In this context, the emerging role of MCT2 in cancer energetics and the parallel metabolic role played by changes in the gut microbiota let us to hypothesize that systemic knock down of MCT2 (KO) in a mouse model of syngeneic lung cancer would not only alter the tumor characteristics, but may also induce significant differences in the gut microbiome and in the fecal and plasma metabolomes. The gene discussed is SLC16A7; the disease is lung carcinoma.